Figure 3 shows that the single CIS dose significantly increased HSPA5 (~9.7-fold), ATF6 (~5.0-fold), DDIT3 (~6.0-fold), and CASP3 (~2.9-fold) levels compared to control. Here, ATF6 is linked to in situ carcinoma.